Metrics to compare | BOLT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBOLTPeersSector | |
|---|---|---|---|---|
P/E Ratio | - | −1.6x | −0.2x | |
PEG Ratio | - | −0.04 | 0.00 | |
Price/Book | 1.8x | 2.0x | 2.6x | |
Price / LTM Sales | - | 9.5x | 2.8x | |
Upside (Analyst Target) | - | 148.8% | 65.0% | |
Fair Value Upside | Unlock | 25.3% | 9.6% | Unlock |
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform. It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.